Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects
Tumor-infiltrating lymphocyte (TIL) therapy has evolved from a pioneering experimental approach to a clinically validated treatment strategy, underscored by the recent approval of lifileucel (Amtagvi) by the Food and Drug Administration (FDA) for advanced melanoma refractory to existing therapies. I...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | Visualized Cancer Medicine |
| Subjects: | |
| Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20250003/vcm20250003.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411329987706880 |
|---|---|
| author | Sarker Drishty Badhon Gonzalez Marian M. Martinez Sophia Sang Qing-Xiang Amy |
| author_facet | Sarker Drishty Badhon Gonzalez Marian M. Martinez Sophia Sang Qing-Xiang Amy |
| author_sort | Sarker Drishty Badhon |
| collection | DOAJ |
| description | Tumor-infiltrating lymphocyte (TIL) therapy has evolved from a pioneering experimental approach to a clinically validated treatment strategy, underscored by the recent approval of lifileucel (Amtagvi) by the Food and Drug Administration (FDA) for advanced melanoma refractory to existing therapies. Initially successful in melanoma due to its high tumor mutational burden (TMB) and immune-reactivity, contemporary efforts extend TIL applications to other solid tumors, including lung, cervical, and colorectal cancers. However, these lower-TMB malignancies typically require the selective enrichment of tumor-specific T cells to achieve significant clinical efficacy. The therapeutic potential of TILs is influenced by critical factors, including cell dose, T-cell phenotype and differentiation state, tumor-specific reactivity, and the ability to persist and expand within patients post-infusion. Emerging techniques, including single-cell transcriptomics and biomarker-guided TIL selection (e.g., CD137, CD103 markers), have provided deeper insights into the characteristics correlating with successful outcomes. Ongoing clinical trials highlight future directions, including genetically engineered TILs with chimeric antigen receptor (CAR) or immune checkpoint knockout, improved cytokine support strategies to enhance T-cell expansion and reduce toxicity, and optimized lymphodepletion regimens. Establishing clear quality attributes for TIL manufacturing will be essential for consistent clinical success, paving the way toward personalized and robust immunotherapeutic approaches across diverse cancer types. |
| format | Article |
| id | doaj-art-e807bcb2c2b54cbd8139c28b50ec6a50 |
| institution | Kabale University |
| issn | 2740-4218 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | Visualized Cancer Medicine |
| spelling | doaj-art-e807bcb2c2b54cbd8139c28b50ec6a502025-08-20T03:34:48ZengEDP SciencesVisualized Cancer Medicine2740-42182025-01-016910.1051/vcm/2025010vcm20250003Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospectsSarker Drishty Badhon0https://orcid.org/0000-0001-6366-3926Gonzalez Marian M.1Martinez Sophia2https://orcid.org/0009-0009-4277-8076Sang Qing-Xiang Amy3https://orcid.org/0000-0001-8828-0569Department of Chemistry and Biochemistry, Florida State UniversityDepartment of Chemistry and Biochemistry, Florida State UniversityDepartment of Chemistry and Biochemistry, Florida State UniversityDepartment of Chemistry and Biochemistry, Florida State UniversityTumor-infiltrating lymphocyte (TIL) therapy has evolved from a pioneering experimental approach to a clinically validated treatment strategy, underscored by the recent approval of lifileucel (Amtagvi) by the Food and Drug Administration (FDA) for advanced melanoma refractory to existing therapies. Initially successful in melanoma due to its high tumor mutational burden (TMB) and immune-reactivity, contemporary efforts extend TIL applications to other solid tumors, including lung, cervical, and colorectal cancers. However, these lower-TMB malignancies typically require the selective enrichment of tumor-specific T cells to achieve significant clinical efficacy. The therapeutic potential of TILs is influenced by critical factors, including cell dose, T-cell phenotype and differentiation state, tumor-specific reactivity, and the ability to persist and expand within patients post-infusion. Emerging techniques, including single-cell transcriptomics and biomarker-guided TIL selection (e.g., CD137, CD103 markers), have provided deeper insights into the characteristics correlating with successful outcomes. Ongoing clinical trials highlight future directions, including genetically engineered TILs with chimeric antigen receptor (CAR) or immune checkpoint knockout, improved cytokine support strategies to enhance T-cell expansion and reduce toxicity, and optimized lymphodepletion regimens. Establishing clear quality attributes for TIL manufacturing will be essential for consistent clinical success, paving the way toward personalized and robust immunotherapeutic approaches across diverse cancer types.https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20250003/vcm20250003.htmltumor-infiltrating lymphocytestil therapyimmunotherapyadoptive cell therapy |
| spellingShingle | Sarker Drishty Badhon Gonzalez Marian M. Martinez Sophia Sang Qing-Xiang Amy Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects Visualized Cancer Medicine tumor-infiltrating lymphocytes til therapy immunotherapy adoptive cell therapy |
| title | Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects |
| title_full | Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects |
| title_fullStr | Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects |
| title_full_unstemmed | Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects |
| title_short | Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects |
| title_sort | tumor infiltrating lymphocyte therapy therapeutic advances and prospects |
| topic | tumor-infiltrating lymphocytes til therapy immunotherapy adoptive cell therapy |
| url | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20250003/vcm20250003.html |
| work_keys_str_mv | AT sarkerdrishtybadhon tumorinfiltratinglymphocytetherapytherapeuticadvancesandprospects AT gonzalezmarianm tumorinfiltratinglymphocytetherapytherapeuticadvancesandprospects AT martinezsophia tumorinfiltratinglymphocytetherapytherapeuticadvancesandprospects AT sangqingxiangamy tumorinfiltratinglymphocytetherapytherapeuticadvancesandprospects |